The refrigerant transition in air conditioning is no longer just about replacing R-410A with something newer. It is about choosing the next product platform. R-410A still dominates the installed base,
On June 28, 2025, SF Express officially broke ground on its Central China Multimodal International Logistics Hub, which project located in the northern zone of the Zhengzhou Airport Economic Experimental
As an indispensable vertical transportation system in modern buildings, an elevator’s safety performance is directly linked to the safety of every passenger. Among its components, the elevator light curtain—the core
When you’re picking out exterior materials for your building, two things pretty much come to mind — durability and looks. Now, Fiber Cement Siding Panels have become a bit of a
Bevel Gear Speed Ratio sets mining equipment apart by balancing torque and speed for demanding tasks. Selecting the correct gear ratio impacts efficiency, energy conservation, heat management, and load handling.
DelveInsight’s, “Eczema Pipeline Insights 2026” Report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Eczema pipeline landscape. It covers the Eczema pipeline drug profiles, including clinical and
DelveInsight’s, “Type 1 Diabetes Pipeline Insight, 2026” report provides comprehensive insights about 85+ companies and 100+ pipeline drugs in Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes
Chronic Myeloid Leukemia (CML) Pipeline Insights There are 20+ key companies, including Renascience, Novartis Pharmaceuticals, Terns Pharmaceuticals, Enliven Therapeutics, MacroGenics, Kartos Therapeutics, AOP Orphan Pharmaceuticals, and others, developing therapies for
Crohn’s Disease Pipeline Insight There are 90+ key companies, including AbbVie, Janssen, Merck, Takeda, Roche, AgomAb Therapeutics, Pfizer, Amgen, and others, developing therapies for Crohn’s disease, with companies like Janssen
Beyond wAIHA, nipocalimab is being studied in several other autoantibody-mediated diseases, including Sjögren’s disease, lupus, and generalized myasthenia gravis (where it is already approved). This multi-indication potential highlights the versatility
